En Es
Categories

Industry News


Thermo LC-MS Solutions Receive ANVISA Registration in Brazil

By Labmedica International staff writers
03 Oct 2017

Image: The Endura MD mass spectrometer (Photo courtesy of Thermo Fisher Scientific).Thermo Fisher Scientific’s (Hampton, NH, USA) liquid chromatography mass spectrometry (LC-MS) in vitro diagnostic (IVD) systems, which enable the quantitation of analytes in complex matrices, have received registration by Brazil’s National Health Surveillance Agency (ANVISA), allowing clinical laboratories in the country to now screen and quantify drugs efficiently.

The Thermo Scientific Endura MD mass spectrometer (MS), Prelude MD high performance liquid chromatography (HPLC) system and ClinQuan MD software have been recognized by ANVISA as capable of meeting its Good Manufacturing Practice (GMP) requirements. This will allow clinical laboratories in Brazil to leverage the high sensitivity and quantitative accuracy of Thermo Fisher Scientific’s LC-MS IVD systems for developing and validating their own methods for the analysis of a large range of drug analytes.

Both Prelude MD and Endura MD combine the capabilities of HPLC with Thermo Scientific TurboFlow technology to enable automated in-line sample cleanup, thus eliminating the need for error-prone manual tasks. Both the systems are powered by the ClinQuan MD software, which is designed to safely store, retrieve and process data from laboratory-developed IVD tests. In line with the Clinical Laboratory Improvements Amendments (CLIA), the software generates time-stamped audit trails to ensure the integrity of results is preserved at all times.

“Clinicians need the flexibility to create and validate their own laboratory-developed tests in order to answer the most complex clinical questions,” said Marc Chalom, applications manager, chromatography and mass spectrometry, Thermo Fisher. “With this in mind, we are expanding our LC-MS IVD product offering to a broader geographical market, so that more labs can benefit from the performance and reliability of our technologies to optimize their workflow”.



E-mail Print
FaceBook Twitter Google+ Linked in

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrated systems for sequencing, flow cytometry and real-time, digital and end point PCR—from sample prep to data analysis. The company’s products and services help increase productivity and efficiency by providing rapid and accurate results for customers in the research, clinical and applied markets.
Gold member
More info

More articles about THERMO FISHER SCIENTIFIC

22 Sep 2021
Thermo Fisher Launches World’s First Fully Integrated Digital PCR (dPCR) System
Thermo Fisher Scientific Inc. (Waltham, MA, USA) has launched the world’s first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results within 90 minutes.
Read More
20 Jan 2021
Thermo Fisher Acquires Point-of-Care Molecular Diagnostics Provider Mesa Biotech
Thermo Fisher Scientific Inc. (Waltham, MA, USA) has entered into a definitive agreement to acquire Mesa Biotech (San Diego, CA, USA), a privately held molecular diagnostic company, for approximately USD 450 million in cash.
Read More
05 Mar 2020
Thermo Fisher Scientific to Acquire QIAGEN N.V.
 Thermo Fisher Scientific Inc. (Waltham, MA, USA) has announced that it plans to acquire QIAGEN N.V. (Venlo, Netherlands), a provider of molecular diagnostics and sample preparation technologies. Thermo Fisher's boards of directors and the managing board of QIAGEN have unanimously approved Thermo Fisher's proposal to acquire QIAGEN.
Read More

Additional news

25 Nov 2021
Global Point of Care Diagnostics Market to Top USD 35 Billion by 2027 Due to Rising Diabetic Cases
The global point of care diagnostics market is projected to grow at a CAGR of close to 6% from more than USD 23 billion in 2020 to over USD 35 billion by 2027, driven by an increase in the number of diabetic cases, technological developments in point of care devices and increased investments by the key players.
Read More
24 Nov 2021
Euromedlab Congress 2021 Postponed as Fourth COVID-19 Wave Hits Germany
The XXIV IFCCEFLM European Congress of Clinical Chemistry and Laboratory Medicine (EuroMedLab Congress 2021) to be held as an in-presence meeting between 28th of November and 2nd of December in Germany has been postponed as the country has been hit very hard by a fourth wave of COVID-19.
Read More
19 Nov 2021
44th World Hospital Congress (WHC) Ends on Upbeat Note as Hospital Leaders Look to Build Resilience
The 44th World Hospital Congress (WHC) organized by The International Hospital Federation (IHF; Geneva, Switzerland) on 8-11 November 2021 in Barcelona, Spain came to an upbeat close.
Read More
16 Nov 2021
Deborah Bowen (USA) Takes Up Position of IHF President for 2021-2023
Deborah Bowen has taken up the position of President of the International Hospital Federation (IHF; Geneva, Switzerland) following her election in 2019 and a two-year term as President Designate.
Read More
16 Nov 2021
IHF and Deloitte Collaborate to Launch Special Interest Group on Leadership for Sustainability
The International Hospital Federation (IHF; Geneva, Switzerland) will collaborate with Deloitte (London, UK) to launch a special interest group (SIG) centered around leadership for sustainability.
Read More
16 Nov 2021
International Hospital Federation (IHF) Announces Winners of IHF Awards 2021
The International Hospital Federation (IHF; Geneva, Switzerland) announced the winners of the IHF Awards 2021 as part of a special ceremony at the 44th World Hospital Congress (WHC) held in Barcelona, Spain.
Read More
13 Nov 2021
GE Healthcare to be Spun Off in 2023 to Create Pure-Play Company at Center of Precision Health
General Electric (GE; Boston, MA, USA) plans to pursue a tax-free spin-off of GE Healthcare, creating a pure-play company at the center of precision health in early 2023.
Read More
11 Nov 2021
Blood Borne Testing Market to Witness Exponential Growth Due to Rising Incidence of Bacterial Infections
The global blood borne testing market is projected to record an exponential CAGR of over 7-8% during 2021-2031, driven by increasing bacterial infection and growing adoption of point of care devices, aided further by technological advancement in devices for blood borne pathogens. These are the latest findings of Fact.MR (Dublin, Ireland), a market research firm.
Read More
10 Nov 2021
AI in Radiology Market Driven by Growing Adoption of Machine Learning Tools in Broad Spectrum of Imaging Applications
The use of AI algorithms in medical image analysis field has made astounding progress. Particularly deep learning has made incessant inroads in radiology practice. The major consumer proposition for companies in the AI in radiology market stems from the exceptional capabilities of AI tools in recognizing complex patterns in the imaging data. These are the latest findings of Transparency Market Research (Albany NY, USA).
Read More
Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions